Terumo Corporation · TSE:4543
Terumo — Investor Presentation (November 2021)
12 slides from Terumo's investor presentation, Nov 4, 2021
Slide 1: A New Stage in US Market Strategy
A New Stage in US Market Strategy Utilize M&A to further build capability and expand presence November 4, 2021 Shinjiro Sato President and CEO Terumo Corporation
Slide 2: Safe Harbor for Forward-Looking Statements and Use of Document
Safe Harbor for Forward-Looking Statements and Use of Document Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future even
Slide 3: TA Achieves Full Lineup of Aortic Products in the US
TA* Achieves Full Lineup of Aortic Products in the US *Terumo Aortic Bolton Stent Graft Interventional therapy Surgery Hybrid Thoracic Thoracic Stent Graft Surgical Graft Hybrid stent graft RelayPro Gelweave Thoraflex Hybrid* *Launch expected next year Abdominal Abdominal Stent Graft Surgical Graft
Slide 4: Growth of US Business & Acquisitions (from 2000)
Growth of US Business & Acquisitions (from 2000) (100M JPY) HOS (US) 2,000 Aortica (US) 1,800 Bolton (US) 1,600 TBCT Angio-Seal (US) 1,400 Sequent (US) GH 1,200 ’99) Cardiovascular 1,000 Div. of 3M (US) CaridianBCT (US) MicroVention (US) 800 C&V 600 Vascutek 400 200 0 FY 00 01 02 03 04 05 06 07 08 0
Slide 5: 20 Years of C&V Business in the US Market
20 Years of C&V Business in the US Market (100M JPY) US market C&V sales trend (Access vs Therapeutic)* 1,400 1,200 Bolton (US) CV Sequent (US) 1,000 TA Angio-Seal (US) Neuro Thera- 800 peutic ’99) Cardiovascular TIS (ex. Access) 600 Div. of 3M (US) MicroVention (US) TIS sales 400 go direct Vascutek
Slide 6: Improved Status in the US
Improved Status in the US Competitor Sales (2019) Sales Growth (2011-2019) Medtronic Edwards J&J B.D. Stryker Terumo 164% B.D. Abbott Boston Intutive Abbott Stryker Zimmer Zimmer Baxter Medtronic Intutive Boston Edwards Olympus Olympus J&J Terumo #12 Baxter 0 2,000 4,000 6,000 8,000 10,000 12,000 14
Slide 7: Trajectory of Sustainable Growth Centered on Acquisitions outside Japan
Trajectory of Sustainable Growth Centered on Acquisitions outside Japan ‘98 ‘00 ‘02 ‘06 ‘11 ‘16 ‘21 SPC* entry BT* TBCT GHP* TMC CV TCVS TERUMO TIS Access Angio-Seal VAK TA Relay, TREO MV WEB ※BT: Blood Transfusion ※SPC: Source Plasma Collection ※GHP: General Hospital Products ©TERUMO CORPORATION 7
Slide 8: Management Capability, Value Chain Evolution
Management Capability, Value Chain Evolution Until the late 90s Now Simply produce and sell items R&D → mfg/sale → improvement that already sold in Japan Products/services that win in the US Terumo Cardiovascular Systems (TCVS) Corp. Terumo BCT, Inc Business HQ R&D, production R&D MicroVention, Inc.
Slide 9: US market Growth Potential in GS26
US market Growth Potential in GS26* *Growth Strategy 26 (next mid- to long-term strategy) • Promote radial access to treat entire body (TIS access products for peripheral, oncology, neurovascular) Cardiac and • Expand TIS products (therapeutic & access) for peripheral, oncology Vascular • Expand the
Slide 10: Potential in the US to Expand Solution Business
Potential in the US to Expand Solution Business The market where new products are born ‖ ＋ Medical Institutions US-style Development Medical cost efficiency Medical Professionals C&V Best solutions Healthcare TBCT w/DX access GH Patients QOL improvement Pharma & Biotechnology companies ©TERUMO CORPO
Slide 11: Era of Fully Leveraging Overall Group Strengths
Era of Fully Leveraging Overall Group Strengths Strengthen Mgmt. Platform (Themes) What (Aims) (1) Account management Adapt to changing purchasing structures (GPO/IDN) (2) DX in business development Differentiate by individualized medicine using digital technology (3) Enhance brand Strengthen Terumo
Slide 12: <“TERUMO
<“TERUMO Si/Ahead (00